CD70/CD27L
Alpha Lifetech can provide CD70/CD27L corresponding products, help each customer's research and development.
01
Introduction To CD70/CD27L
Drug targets a biomolecule that can directly bind to drugs and then react. Generally, the target refers to a protein, which is related to the cause of disease. The focus of the target began with focusing on tumors and then began to spread to various fields. Introduction to CD70/CD27L protein is a common target in medicine.
CD70, also known as CD27L, is the sole ligand of CD27 and is a tightly regulated transmembrane glycoprotein expressed on B lymphocytes, T lymphocytes, and APC. CD70 shares structural similarities to other members of the TNF superfamily (TNF α, FasL, RANKL, TRAIL, 4-1 BBL, CD30L, and CD40L). In the normal physiological state, CD70 is expressed only in the thymus and lamina propria.
Function of Target CD70/CD27L
In pro-inflammatory states (infection, malignancy, autoimmune status), CD27-CD70 activity increases lymphocyte proliferation and survival with multiple downstream effects. CD27-CD70 signaling was also shown to promote B cell activation and terminal differentiation into plasma cells, increase cytotoxic CD8 + T cell activity, promote TNF- α production by T cells, and increase NK cell activity through production of IFN- γ and IL-2. The indirect killing mechanism is mainly mediated through the action of CD27 and CD70 on NK cells to release perforin and cytokines on NK cells, thus activating cytotoxic T lymphocytes (CTL) to further kill tumor cells.
Gene Pathway of Target CD70/CD27L
Upon binding of CD27 to its ligand CD70, it triggers a series of signaling events. This binding is specific, and CD70 exists as a trimeric form to bind to the three disulfide bridges of CD27. Upon binding to CD70, CD27 transmits a signal into the cell through the signal transduction domain of its cytoplasmic tail. These signals may include the recruitment and activation of the TRAF (TNF-related factors) family, which in turn trigger the activation of downstream signaling pathways. Activation of TRAFs further triggers activation of downstream signaling pathways, including activation of NF- κ B (nuclear factor κ B) and JNK (c-Jun N-terminal kinase) pathways. Activation of these pathways is crucial for regulating processes such as cell proliferation, differentiation, apoptosis as well as immune response. The CD27 – CD70 interaction provides a potent second signal for the initiation of CD4-dependent and CD8-independent T cells during tumor clearance. The interaction between CD70 and CD27 provides a critical co-stimulatory signal for T cells.
Fig 1: CD70 Gene Pathway. (Reference source: Flieswasser T, Van den Eynde A, et al,. The CD70-CD27 axis in oncology: the new kids on the block. J Exp Clin Cancer Res. 2022 Jan 6;41(1):12.)
Alpha Lifetech Can Provide
At present, various drugs targeting CD70/CD27L are constantly under development, and taking drugs alone or together with other products to treat diseases has become a new method and remarkable achievements have been made. CD70/CD27L protein has shown important research value and application prospects in tumor biology, and drug research and development. With further research and technological advances, CD70/CD27L protein products are also essential. Alpha Lifetech can provide CD70/CD27L corresponding products and help each customer's research and development. Alpha Lifetech focuses on high-precision detection development and validation services to support drug screening and biosimilar discovery. Our detection methods, including ELISA, cell-based functional testing, and flow cytometry, have undergone rigorous sensitivity, specificity, and reproducibility testing. In addition to testing and development, our team also provides data analysis, scheme optimization, and cross-species reactivity testing to ensure reliable results.
| Catalog Number | Product Name | Product Sizes |
|---|---|---|
| ALP64647 | 50ug,100ug,500ug | |
| ALP64525 | ALP64525-Recombinant Human CD70/CD27L Protein, mFc Tag | 100ug,1mg,5mg |
| ADT1156 | 100ug,1mg,5mg | |
| ADT1710 | ADT1710-Vorsetuzumab Biosimilar-Anti CD70/TNFSF7 mAb- Research Grade |
100ug,1mg,5mg |
Reference
[1] Nilsson MB, Yang Y, Heeke S, Patel SA, Poteete A, Udagawa H, Elamin YY, Moran CA, Kashima Y, Arumugam T, Yu X, Ren X, Diao L, Shen L, Wang Q, Zhang M, Robichaux JP, Shi C, Pfeil AN, Tran H, Gibbons DL, Bock J, Wang J, Minna JD, Kobayashi SS, Le X, Heymach JV. CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance. Cancer Cell. 2023 Feb 13;41(2):340-355.e6.
[2] Jacobs J, Deschoolmeester V, Zwaenepoel K, Rolfo C, Silence K, Rottey S, Lardon F, Smits E, Pauwels P. CD70: An emerging target in cancer immunotherapy. Pharmacol Ther. 2015 Nov;155:1-10.
[3] Flieswasser T, Van den Eynde A, Van Audenaerde J, De Waele J, Lardon F, Riether C, de Haard H, Smits E, Pauwels P, Jacobs J. The CD70-CD27 axis in oncology: the new kids on the block. J Exp Clin Cancer Res. 2022 Jan 6;41(1):12.
Video Resources
If you have any questions, please feel free to contact us at any time.
Leave Your Message
2018-07-16
0102